Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1396 | Enoxaparin Wiki | 0.27 |
| drug2365 | Methylprednisolone Wiki | 0.27 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
Navigate: Correlations HPO
There is one clinical trial.
SARS-CoV-2 infection seems to induce in most critical cases an excessive and aberrant hyper-inflammatory host immune response that is associated with a so-called "cytokine storm", moreover pro-thrombotic derangements of haemostatic system is another common finding in most severe forms of COVID19 infections, which may be explained by the activation of coagulative cascade primed by inflammatory stimuli, in line with what is observed in many other forms of sepsis. Targeting inflammatory responses exploiting steroids' anti-inflammatory activity along with thrombosis prevention may be a promising therapeutic option to improve patients' outcome. Despite the biological plausibility, no good evidence is available on the efficacy and safety of heparin on sepsis patients, and many issues have to be addressed, regarding the proper timing, dosages and administration schedules of anticoagulant drugs. The primary objective is to assess the hypothesis that an adjunctive therapy with steroids and unfractionated heparin (UFH) or with steroids and low molecular weight heparin (LMWH) are more effective in reducing any-cause mortality in critically-ill patients with pneumonia from COVID- 19 infection compared to low molecular weight heparin (LMWH) alone. Mortality will be measured at 28 days. The study is designed as a multicenter, national, interventional, randomized, investigator sponsored, three arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned in a ratio 1:1:1 to one of the three treatment groups: LMWH group, LMWH+steroids or UFH+steroid group. A possible result showing the efficacy of the composite treatment in reducing the mortality rate among critically ill patients with pneumonia from COVID-19 infection will lead to a revision of the current clinical approach to this disease.
Description: All-cause mortality at day 28, defined as the comparison of proportions of patients death for any cause at day 28 from randomization.
Measure: All-cause mortality at day 28 Time: Day 28 from randomizationDescription: All-cause mortality at ICU discharge, defined as the comparison of proportions of patients death for any cause at ICU discharge.
Measure: All-cause mortality at ICU discharge Time: from randomization to ICU discharge, censored at day 30Description: All-cause mortality at Hospital discharge, defined as the comparison of proportions of patients death for any cause at hospital discharge
Measure: All-cause mortality at hospital discharge Time: from randomization to ICU discharge, censored at day 90Description: Occurrence of rescue administration of high-dose steroids or immune-modulatory drugs
Measure: Need of rescue administration of high-dose steroids or immune-modulatory drugs Time: from randomization to ICU discharge, censored at day 28Description: Occurrence of new organ dysfunction during ICU stay. Organ dysfunction is defined as a Sequential Organ Failure Assessment (SOFA) score ≥3 for the corresponding organ occurring after randomization.
Measure: New organ dysfunction during ICU stay Time: From randomization to ICU discharge, censored at day 28Description: Grade of organ dysfunction during ICU stay, grade of dysfunction is measured with Sequential Organ Failure Assessment (SOFA) score daily from randomization to day 28 or ICU discharge.
Measure: Grade of organ dysfunction during ICU stay Time: From randomization to ICU discharge, censored at day 28Description: Total number of days between ICU discharge and day 28. If death occurs during the ICU stay before day 28 the ICU free days calculation will be 0. The ICU readmission before day 28 after randomization will be considered.
Measure: ICU free days at day 28 Time: From randomization to day 28Description: Occurrence of new infections including bacterial infections, fungal infections by Candida, Aspergillus, and viral reactivations including Adenovirus, Herpes Virus e Cytomegalovirus
Measure: Occurrence of new infections Time: from randomization to day 28Description: Total number of days that patient is alive and free of ventilation between randomisation and day 28. Ventilation is considered as positive pressure ventilation, either invasive or non-invasive. Periods of assisted breathing lasting less than 24 hours for surgical procedures will not count against the ventilation free days calculation.
Measure: Ventilation free days at day 28 Time: From randomization to day 28, censored at hospital dischargeDescription: Total number of days that patient is alive and free of vasopressors between randomisation and day 28.
Measure: Vasopressors free-days at day 28 Time: From randomization to day 28, censored at hospital dischargeDescription: Occurrence of switch from non-invasive to invasive mechanical ventilation
Measure: Switch from non-invasive to invasive mechanical ventilation Time: from randomization to ICU discharge, censored at day 28Description: Total number of hours from start of non-invasive to invasive ventilation to switch to invasive ventilation
Measure: Delay from start of non-invasive ventilation to switch to invasive ventilation Time: from randomization to ICU discharge, censored at day 28Description: Adverse events occurred from randomization to day 28. Events that are part of the natural history of the primary disease process or expected complications of critical illness will not be reported as adverse events.
Measure: Occurrence of protocol related adverse events Time: From randomization to day 28Description: Occurrence of objectively confirmed venous thromboembolism, stroke or myocardial infarction
Measure: Occurrence of venous thromboembolism, stroke or myocardial infarction Time: from randomization to ICU discharge, censored at day 28Description: Occurrence of major bleeding defined as transfusion of 2 or more units of packed red blood cells in a day, bleeding that occurs in at least one of the following critical sites [intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal], bleeding that necessitates surgical intervention and bleeding that is fatal (defined as a bleeding event that was the primary cause of death or contributed directly to death)
Measure: Occurrence of major bleeding (safety end point) Time: from randomization to ICU discharge, censored at day 28Description: Occurrence of clinically relevant non-major bleeding defined ad acute clinically overt bleeding that does not meet the criteria for major and consists of any bleeding compromising hemodynamic; spontaneous hematoma larger than 25 cm2, or 100 cm2, intramuscular hematoma documented by ultrasonography, haematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures; haemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention or any other bleeding requiring temporary cessation of a study drug.
Measure: Occurrence of clinically relevant non-major bleeding (safety end point) Time: from randomization to ICU discharge, censored at day 28Description: Mean arterial pressure will be measured in millimeters of mercury
Measure: Mean arterial pressure Time: Daily from inclusion until ICU discharge, censored day 28Description: hearth rate will be measured in beats per minute
Measure: hearth rate Time: Daily from inclusion until ICU discharge, censored day 28Description: respiratory rate will be measured in breaths per minute
Measure: respiratory rate Time: Daily from inclusion until ICU discharge, censored day 28Description: diuresis will be measured daily in milliliters of urine output in the previous 24 hours
Measure: diuresis Time: Daily from inclusion until ICU discharge, censored day 28Description: systemic body temperature will be measured in celsius degrees
Measure: systemic body temperature Time: Daily from inclusion until ICU discharge, censored day 28Description: fluid balance will be measured in milliliters of fluids input and output in the previous 24 hours
Measure: fluid balance Time: Daily from inclusion until ICU discharge, censored day 28Description: Haemoglobin will be measured in mg/dl
Measure: Haemoglobin concentration Time: Daily from inclusion to ICU discharge (censored at day 28)Description: platelets count will be measured in U 10^3/mm^3
Measure: platelets count Time: Daily from inclusion to ICU discharge (censored at day 28)Description: white blood cells count will be measured in U per 10^9/L
Measure: white blood cells count Time: Daily from inclusion to ICU discharge (censored at day 28)Description: troponin will be measured in µg/L
Measure: troponin Time: Daily from inclusion to ICU discharge (censored at day 28)Description: coagulative function will be measured with parameters INR, PT, aPTT
Measure: coagulative function Time: Daily from inclusion to ICU discharge (censored at day 28)Description: D-dimer will be measured in µg/ml
Measure: D-dimer Time: Daily from inclusion to ICU discharge (censored at day 28)Description: anti-thrombin will be measured as a percentage
Measure: anti-thrombin Time: Daily from inclusion to ICU discharge (censored at day 28)Description: liver function will be assessed through measurement of AST, ALT in U/L
Measure: Liver function Time: Daily from inclusion to ICU discharge (censored at day 28)Description: Bilirubin will be measured in mg/dL
Measure: Bilirubin Time: Daily from inclusion to ICU discharge (censored at day 28)Description: Creatinine will be measured in mg/dL
Measure: Creatinine Time: Daily from inclusion to ICU discharge (censored at day 28)Description: Blood cells count will be measured in Units per x 10^9/L of blood
Measure: Blood cells count Time: daily from inclusion to ICU discharge (censored at day 28)Description: C-reactive protein (CRP) will be measured in mg/dl
Measure: C-reactive protein (CRP) Time: daily from inclusion to ICU discharge (censored at day 28)Description: procalcitonin(PCT) wiull be measured in ng/ml
Measure: procalcitonin(PCT) Time: daily from inclusion to ICU discharge (censored at day 28)Description: interleukin 6 (IL-6) will be measured in pg/ml
Measure: interleukin 6 (IL-6) Time: daily from inclusion to ICU discharge (censored at day 28)Description: Ventilation mode will be cathegorized in spontaneous breathing, invasive or non invasive ventilation
Measure: Ventilation mode Time: Daily from inclusion to ICU discharge (censored at day 28)Description: inspired oxygen fraction will be measured in percentage of oxygen in inspired air
Measure: inspired oxygen fraction Time: Daily from inclusion to ICU discharge (censored at day 28)Description: Gas exchanges will be assessed by measurement of PaO2, PaCO2 in mmHg by arterial blood gas analysis
Measure: Gas exchanges Time: Daily from inclusion to ICU discharge (censored at day 28)Description: lactates will be measured in mMol/L
Measure: lactates Time: Daily from inclusion to ICU discharge (censored at day 28)Description: pH will be measured in pH scale
Measure: pH Time: Daily from inclusion to ICU discharge (censored at day 28)Description: oxygen saturation in blood will be measured in arterial and venous samples in percentage values
Measure: oxygen saturation in blood Time: Daily from inclusion to ICU discharge (censored at day 28)Description: New blood, respiratory and urinary-tract infections will be recorded
Measure: New infections Time: From randomization to day 28Description: Viral reactivation measured by CMV DNA titres will be recorded.
Measure: Viral reactivation Time: From randomization to day 28Description: Need of new renal replacement therapy (intermittent haemodialysis or continuous veno-venous hemofiltration) will be recorded.
Measure: Need of new renal replacement therapy Time: from randomization to day 28Description: Adjunctive treatment such as pronation cycles, Nitric Oxide or ECMO will be recorded
Measure: Adjunctive treatments Time: from randomization to ICU discharge (censored at day 28);Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports